Monika A. Myszczynska

Monika A. Myszczynska

Auto-generated profile, based on publicly available information

Monika A. Myszczynska

Sheffield Institute for Translational Neuroscience, Department of Neuroscience, University of Sheffield, 385a Glossop Road, Sheffield S10 2HQ, United Kingdom

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2020 in Nature Reviews Neurology
Verified
Journal Article
Closed access
PDF file
MMMonika A. Myszczynska
Monika A. Myszczynska
POPoojitha N. Ojamies
Poojitha N. Ojamies
ALAlix M. B. Lacoste
Alix M. B. Lacoste
DNDaniel Neil
Daniel Neil
ASAmir Saffari
Amir Saffari
LFLaura Ferraiuolo
Laura Ferraiuolo

22 June 2016 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
CWChristopher P Webster
Christopher P Webster
ESEmma F Smith
Emma F Smith
CBClaudia S Bauer
Claudia S Bauer
AMAnnekathrin Moller
Annekathrin Moller
GHGuillaume Hautbergue
Guillaume Hautbergue
KVKurt J. De Vos
Kurt J. De Vos
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

5 July 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
GHGuillaume Hautbergue
Guillaume Hautbergue
LCLydia M. Castelli
Lydia M. Castelli
LFLaura Ferraiuolo
Laura Ferraiuolo
ASAlvaro Sanchez-Martinez
Alvaro Sanchez-Martinez
JCJohnathan Cooper-Knock
Johnathan Cooper-Knock
PSPamela Jean Shaw
Pamela Jean Shaw
Hexanucleotide repeat expansions in theC9ORF72gene are the commonest known genetic cause of amyotrophic lateral sclerosis and frontotemporal dementia. Expression of repeat transcripts and dipeptide repeat proteins trigger multiple mechanisms of neurotoxicity. How repeat transcripts get exported from the nucleus is unknown. Here, we show that depletion of the nuclear export adaptor SRSF1 prevents neurodegeneration and locomotor deficits in aDrosophilamodel of C9ORF72-related disease. This intervention suppresses cell death of patient-derived motor neuron and astrocytic-mediated neurotoxicity in co-culture assays. We further demonstrate that either depleting SRSF1 or preventing its interaction with NXF1 specifically inhibits the nuclear export of pathologicalC9ORF72transcripts, the production of dipeptide-repeat proteins and alleviates neurotoxicity inDrosophila, patient-derived neurons and neuronal cell models. Taken together, we show that repeat RNA-sequestration of SRSF1 triggers the NXF1-dependent nuclear export ofC9ORF72transcripts retaining expanded hexanucleotide repeats and reveal a novel promising therapeutic target for neuroprotection.

1 September 2018 in Molecular Therapy Nucleic Acids
Verified
Journal Article
Open access
TITommaso Iannitti
Tommaso Iannitti
JSJoseph M. Scarrott
Joseph M. Scarrott
SLShibi Likhite
Shibi Likhite
ICIan R.P. Coldicott
Ian R.P. Coldicott
KLKatherine E. Lewis
Katherine E. Lewis
MAMimoun Azzouz
Mimoun Azzouz
Of familial amyotrophic lateral sclerosis (fALS) cases, 20% are caused by mutations in the gene encoding human cytosolic Cu/Zn superoxide dismutase (hSOD1). Efficient translation of the therapeutic potential of RNAi for the treatment of SOD1-ALS patients requires the development of vectors that are free of significant off-target effects and with reliable biomarkers to discern sufficient target engagement and correct dosing. Using adeno-associated virus serotype 9 to deliver RNAi against hSOD1 in the SOD1G93A mouse model, we found that intrathecal injection of the therapeutic vector via the cisterna magna delayed onset of disease, decreased motor neuron death at end stage by up to 88%, and prolonged the median survival of SOD1G93A mice by up to 42%. To our knowledge, this is the first report to demonstrate no significant off-target effects linked to hSOD1 silencing, providing further confidence in the specificity of this approach. We also report the measurement of cerebrospinal fluid (CSF) hSOD1 protein levels as a biomarker of effective dosing and efficacy of hSOD1 knockdown. Together, these data provide further confidence in the safety of the clinical therapeutic vector. The CSF biomarker will be a useful measure of biological activity for translation into human clinical trials.

22 March 2016 in Brain Pathology
Verified
Journal Article
Closed access
PDF file
MMMonika Myszczynska
Monika Myszczynska
LFLaura Ferraiuolo
Laura Ferraiuolo

1 September 2018 in Biochimica et Biophysica Acta (BBA) - Bioenergetics
Verified
Journal Article
Closed access
SAScott P. Allen
Scott P. Allen
BHBenjamin Hall
Benjamin Hall
LCLydia Castelli
Lydia Castelli
LFLaura Francis
Laura Francis
RWRyan Woof
Ryan Woof
PSPamela J. Shaw
Pamela J. Shaw